Christopher Cabell

Christopher Cabell is a declared insider at 3 companies; the most frequent names are Arena Pharmaceuticals Inc, Inhibikase Therapeutics, Inc. and Zura Bio Ltd. We count 6 filings; the first trade dates from 15 July 2020 and the latest from 21 February 2026.

The open-market record consists of 1 sale worth €774k, with no purchase. Outside the open market, there are 2 share grants and 2 option exercises.

The latest filing, published on 24 February 2026, reports a transaction in Inhibikase Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.